N/A
Manufactured by Seroyal USA
56 FDA adverse event reports analyzed
Last updated: 2026-04-15
CALENDULA OFFICINALIS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Seroyal USA. The most commonly reported adverse reactions for CALENDULA OFFICINALIS include DRUG INEFFECTIVE, ERYTHEMA, FEBRILE NEUTROPENIA, ABDOMINAL PAIN, ACUTE VESTIBULAR SYNDROME. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CALENDULA OFFICINALIS.
Out of 10 classified reports for CALENDULA OFFICINALIS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 56 FDA FAERS reports that mention CALENDULA OFFICINALIS. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, ERYTHEMA, FEBRILE NEUTROPENIA, ABDOMINAL PAIN, ACUTE VESTIBULAR SYNDROME, APPLICATION SITE BURN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Seroyal USA in connection with CALENDULA OFFICINALIS. Always verify the specific product and NDC with your pharmacist.